#USA #stock offering #Henderson #VolitionRx #epigenetics

VolitionRx: Innovating Epigenetics with New Offering

VolitionRx Limited, a leader in the field of epigenetics, has announced an exciting new financial development that could significantly enhance its ongoing research and product development initiatives. The company, which trades on the NYSE AMERICAN under the ticker VNRX, has revealed plans to launch a registered direct offering aimed at raising up to $1.9 million. This capital injection is strategically targeted at furthering Volition's mission to advance the understanding and application of epigenetic science in the medical field.

Direct Offering Breakdown

The offering involves the sale of 445,648 shares of common stock to certain insiders, including directors and executive officers, at an attractive price of $0.5722 per share. In addition, it encompasses the distribution of a more substantial 2,857,389 shares along with common stock purchase warrants to external investors. The warrants consist of Form A warrants for purchasing up to 2,857,389 shares and Form B warrants for an additional 1,428,693 shares. These warrants have designated exercise prices of $0.5722 and $0.71525, respectively, and provide investors an opportunity to increase their stakes in the company as they can be exercised immediately, lasting for a five-year period from issuance.

The offering is expected to close around December 9, 2024, pending the fulfillment of customary closing conditions, and does not involve any placement agents, highlighting the company's direct engagement strategy.

Utilization of Funds

The proceeds from this offering are projected to reach up to $1.9 million, before accounting for any estimated expenses related to the offering. Importantly, if the warrants are fully exercised, VolitionRx anticipates receiving an additional $2.7 million. These funds are earmarked for various critical functions, including:

• - Research and Development: Strengthening the company’s efforts towards innovative discoveries in epigenetic science.
• - Clinical Studies: Supporting ongoing clinical trials necessary for regulatory approval and further research.
• - Product Commercialization: Enhancing market readiness for their epigenetic-based diagnostics and therapeutic products.
• - General Corporate Purposes: Including working capital needs to maintain operational efficiencies.

About Volition

VolitionRx operates at the forefront of epigenetic research, with a firm dedication to providing groundbreaking solutions aimed at early disease detection. With a global footprint that includes research facilities in Belgium and innovation laboratories in Nevada, London, and Singapore, the company's strategic locations facilitate a robust pipeline of product development.

Through its subsidiaries, VolitionRx is committed to creating simple and cost-effective blood tests that serve as diagnostic tools for a variety of diseases ranging from cancers to conditions related to NETosis, including sepsis. The company's focus on early detection is poised to have a dual impact: not only does it aim to prolong the lives of patients, but it also strives to enhance their quality of life.

For more information on the prospectus related to the offering, interested parties are encouraged to visit the Securities and Exchange Commission's website. This offering exemplifies VolitionRx's proactive steps towards capitalizing on financial opportunities to sustain their innovative research agenda and ultimately fulfill their vision of improving health outcomes through earlier disease detection.

Conclusion

In summary, VolitionRx’s recent announcement signifies a critical step in its journey as a pioneering force in epigenetics. By leveraging this offering, the company is not just seeking to boost its financial reserves; it is affirmatively laying the groundwork for future innovations that could transform diagnostics and treatments in healthcare.